Circulating biomarkers to monitor cancer progression and treatment
Tumor heterogeneity is a major challenge and the root cause of resistance to treatment. Still, the standard diagnostic approach relies on the analysis of a single tumor sample from a local or metastatic site that is obtained at a given time point. Due to intratumoral heterogeneity and selection of s...
Principais autores: | Suthee Rapisuwon, Eveline E. Vietsch, Anton Wellstein |
---|---|
Formato: | Artigo |
Idioma: | English |
Publicado em: |
Elsevier
2016-01-01
|
coleção: | Computational and Structural Biotechnology Journal |
Assuntos: | |
Acesso em linha: | http://www.sciencedirect.com/science/article/pii/S2001037016300113 |
Registros relacionados
-
Circulating cell-free nucleic acids of plasma in human aging, healthy aging and longevity: current state of knowledge
por: Nicolas P. Tessier, et al.
Publicado em: (2023-11-01) -
Circulating Cell-free Tumor Nucleic Acids in Gastric Cancer
por: Hyun-Ji Lee, et al.
Publicado em: (2018-09-01) -
The Role of Circulating Biomarkers in Lung Cancer
por: Sayuri Herath, et al.
Publicado em: (2022-01-01) -
Liquid biopsy in gallbladder carcinoma: Current evidence and future prospective
por: Sridhar Mishra, et al.
Publicado em: (2024-12-01) -
Longitudinal Study of Circulating Biomarkers in Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Pablo J. Dopico, et al.
Publicado em: (2022-03-01)